EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.
“First off, we are significantly better positioned to support continued Avenova growth having entered into a $10.3 million financing with accredited investors under favorable pricing terms and no warrant coverage,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “This agreement, which was struck with investors who have NovaBay’s long-term interest in mind, removes the financing overhang and NYSE compliance issues, and is expected to close in the first quarter of 2018.
“We enjoyed continued success with our focus on increasing Avenova sales through the high-margin retail pharmacy channel during the third quarter, with prescription sales increasing 67% over the prior year and representing more than 90% of total Avenova sales. Gross margin on Avenova sales reached a record 92% for the quarter, exceeding our 2017 guidance,” he said.
“As anticipated, we benefitted from a higher net price per unit in the third quarter as more insurance deductibles were satisfied. However, the improvement did not fully offset the higher-than-anticipated impact of rebates in the first half of 2017,” added Sieczkarek. “As a result, we are revising our 2017 net sales guidance to be between $17.5 million and $18.5 million, representing a 47% to 55% increase over 2016.
“Two years ago, we focused NovaBay on commercializing Avenova – a new paradigm in treating the underlying cause rather than the symptoms of blepharitis and dry eye. Since then we established a base of more than 11,300 medical professionals who have prescribed Avenova and collected data showing reimbursement trends. We are using this information to more precisely target high prescribers with the goal of increasing the number of prescriptions written per prescriber,” he added. “This strategy is aimed at optimizing sales by effectively allocating our resources.”
$10.3 Million Financing
On November 13, 2017, the Company entered into a share purchase agreement for the sale of an aggregate of 2,400,000 shares of the Company’s common stock, to a single accredited investor for an aggregate purchase price of $10,320,000. The Private Placement is expected to close in January 2018.
Key Third Quarter Metrics
- Sales of $4.1 million increased 19% year-over-year;
- Prescription sales into the pharmacy channel were $3.5 million, up 67% year-over-year;
- Prescription sales represented 90% of total Avenova sales;
- Gross margin on Avenova sales was 92%;
- New prescribers were more than 730; and
- Total number of medical professionals who have prescribed Avenova exceeded 11,300, up 47% year-over-year and up 7% from the second quarter of 2017.
Third Quarter 2017 Financial Results
Net sales for the third quarter of 2017 increased 19% to $4.1 million from $3.4 million for the third quarter of 2016. Gross margin on net sales improved to 87% for the third quarter of 2017 from 84% for the third quarter of 2016. Gross margin on Avenova sales was 92% for the third quarter of 2017 compared with 88% for the prior-year period.
Sales and marketing expenses for the third quarter of 2017 were $3.3 million compared with $2.7 million for the prior-year period, with the increase primarily due to an increase in the number of sales representatives and increased sampling and marketing programs. G&A expenses for the third quarters of 2017 and 2016 were unchanged at $2.3 million. R&D expenses for the third quarter of 2017 were $132,000 compared with $4,000 for the third quarter of 2016, with the increase primarily due to a gain recognized from the sales of laboratory equipment in the third quarter of 2016. Operating loss for the third quarter of 2017 was $2.2 million, up slightly from $2.1 million for the third quarter of 2016.
Non-cash loss on the change of fair value of warrant liability for the third quarter of 2017 was $281,000 compared with a non-cash loss of $1.7 million for the third quarter of 2016.
The net loss for the third quarter of 2017 was $2.4 million, or $0.16 per share, compared with a net loss for the third quarter of 2016 of $3.7 million, or $0.34 per share.
Nine-Month 2017 Financial Results
Net sales for the nine months ended September 30, 2017 were $11.9 million, up 52% from $7.8 million for the nine months ended September 30, 2016. Gross margin on net sales improved to 85% for the nine-month period of 2017 from 79% for the nine-month period in 2016. Gross margin on Avenova sales improved to 90% for the first nine months of 2017 from 85% for the first nine months of 2016.
Sales and marketing expenses for the nine months ended September 30, 2017 were $10.4 million and G&A expenses were $7.1 million, a 20% and 36% increase, respectively, compared with the nine months ended September 30, 2016. R&D expenses for the first nine months of 2017 were $264,000, a 78% decrease from the first nine months of 2016. Operating loss for the first nine months of 2017 was $7.7 million, a 14% improvement from $9.0 million for the comparable period in 2016.
Non-cash loss on the change of fair value of warrant liability for the first nine months of 2017 was $501,000 compared with a non-cash loss of $2.5 million for the first nine months of 2016.
The net loss for the nine months ended September 30, 2017 was $8.2 million, or $0.54 per share, compared with a net loss for the nine months ended September 30, 2016 of $11.5 million, or $1.54 per share.
NovaBay had cash and cash equivalents of $6.1 million as of September 30, 2017, compared with $9.5 million as of December 31, 2016. In November 2017, the Company entered into a private placement agreement expected to raise gross proceeds of $10.3 million in the first quarter of 2018.
The Company used $3.3 million in cash to fund operations during the nine months ended September 30, 2017, a significant improvement from $11.4 million used during the nine months ended September 30, 2016. The decrease in cash usage was primarily due to higher sales of Avenova, increased accounts receivable collections, lower prepaid expenses resulting from bringing the sales team in-house during the first quarter of 2017, and increased payment of payables during the nine months ended September 30, 2016 resulting from increased financing activities.
2017 Financial Outlook
- NovaBay is revising guidance for 2017 net sales to be between $17.5 million and $18.5 million, a 47% to 55% increase over 2016. This compares with previous guidance for 2017 net sales to be $19 million.
- The Company is affirming its guidance for 2017 gross profit margin on Avenova sales to be in the high 80% range.
Conference Call
NovaBay management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-608-8202 from within the U.S. or 702-495-1913 from outside the U.S., with the conference identification number 3187119.
A live webcast of the call will be available at http://novabay.com/investors/events and will be archived for 90 days.
A replay of the call will be available beginning two hours after call completion through 11:59 p.m. Eastern time December 14, 2017 by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 3187119.
About Avenova®
Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our expected equity financing, estimated annual revenue, expected operating losses, gross margin, the future sales of our products, and generally the Company’s expected future financial results. Forward-looking statements can be identified with words like (and variations of): “guidance,” and “expect.” These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company's products, unexpected adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company's intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit NovaBay’s Website
| NOVABAY PHARMACEUTICALS, INC. | |||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
| (Unaudited) | |||||||||||
| (In thousands) | |||||||||||
| September 30, | December 31, | ||||||||||
| 2017 | 2016 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 6,076 | $ | 9,512 | |||||||
| Accounts receivable, net of allowance for doubtful accounts ($28 and $10 at September 30, 2017 and December 31, 2016, respectively) | 2,230 | 2,120 | |||||||||
| Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimate net realizable value adjustments of $139 and $196 at September 30, 2017 and December 31, 2016, respectively | 599 | 873 | |||||||||
| Prepaid expenses and other current assets | 1,033 | 1,966 | |||||||||
| Total current assets | 9,938 | 14,471 | |||||||||
| Property and equipment, net | 492 | 371 | |||||||||
| Other assets | 626 | 539 | |||||||||
| TOTAL ASSETS | $ | 11,056 | $ | 15,381 | |||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
| Liabilities: | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 356 | $ | 455 | |||||||
| Accrued liabilities | 2,419 | 2,007 | |||||||||
| Deferred revenue | 2,487 | 1,861 | |||||||||
| Total current liabilities | 5,262 | 4,323 | |||||||||
| Deferred revenues - non-current | 1,569 | 1,986 | |||||||||
| Deferred rent | 286 | 327 | |||||||||
| Warrant liability | 1,889 | 1,446 | |||||||||
| Other liabilities | 218 | 198 | |||||||||
| Total liabilities | 9,224 | 8,280 | |||||||||
| Stockholders' equity : | |||||||||||
| Preferred stock: 5,000 shares authorized; none outstanding at September 30, 2017 and December 31, 2016 | — | — | |||||||||
|
Common stock, $0.01 par value; 240,000, shares authorized 15,361 and 15,269 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively |
154 | 153 | |||||||||
| Additional paid-in capital | 113,545 | 110,619 | |||||||||
| Accumulated deficit | (111,867 | ) | (103,671 | ) | |||||||
| Total stockholders' equity | 1,832 | 7,101 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 11,056 | $ | 15,381 | |||||||
|
NOVABAY PHARMACEUTICALS, INC. |
|||||||||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
|||||||||||||||||
|
(Unaudited) |
|||||||||||||||||
|
(In thousands, except per share data) |
|||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
|
|
September 30, |
|
September 30, |
||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||||
| Sales: | |||||||||||||||||
| Product revenue, net | $ | 4,080 | $ | 3,262 | $ | 11,868 | $ | 7,571 | |||||||||
| Other revenue,net | 11 | 176 | 46 | 249 | |||||||||||||
| Total net sales | 4,091 | 3,438 | 11,914 | 7,820 | |||||||||||||
| Product cost of goods sold | 521 | 566 | 1,807 | 1,656 | |||||||||||||
| Gross profit | 3,570 | 2,872 | 10,107 | 6,164 | |||||||||||||
| Research and development | 132 | 4 | 264 | 1,215 | |||||||||||||
| Sales and marketing | 3,296 | 2,663 | 10,412 | 8,660 | |||||||||||||
| General and administrative | 2,311 | 2,266 | 7,134 | 5,241 | |||||||||||||
| Total operating expenses | 5,739 | 4,933 | 17,810 | 15,116 | |||||||||||||
| Operating Loss | (2,169 | ) | (2,061 | ) | (7,703 | ) | (8,952 | ) | |||||||||
| Non-cash loss on changes in fair value of warrant liability | (281 | ) | (1,671 | ) | (501 | ) | (2,480 | ) | |||||||||
| Other income (expense), net | 3 | (4 | ) | 9 | (69 | ) | |||||||||||
| Loss before provision for income taxes | (2,447 | ) | (3,736 | ) | (8,195 | ) | (11,501 | ) | |||||||||
| Provision for income tax | - | - | (1 | ) | (2 | ) | |||||||||||
| Net loss and comprehensive loss | $ | (2,447 | ) | $ | (3,736 | ) | $ | (8,196 | ) | $ | (11,503 | ) | |||||
| Net loss per share attributable to common stockholders (basic and diluted) | $ | (0.16 | ) | $ | (0.34 | ) | $ | (0.54 | ) | $ | (1.54 | ) | |||||
| Weighted-average shares of common stock outstanding used in computing net loss per share of common stock | 15,324 | 10,913 | 15,306 | 7,481 | |||||||||||||
